Literature DB >> 22664970

Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints.

Jose M Munita1, Diana Panesso, Lorena Diaz, Truc T Tran, Jinnethe Reyes, Audrey Wanger, Barbara E Murray, Cesar A Arias.   

Abstract

Mutations in liaFSR, a three-component regulatory system controlling cell-envelope stress response, were recently linked with the emergence of daptomycin (DAP) resistance in enterococci. Our previous work showed that a liaF mutation increased the DAP MIC of a vancomycin-resistant Enterococcus faecalis strain from 1 to 3 μg/ml (the DAP breakpoint is 4 μg/ml), suggesting that mutations in the liaFSR system could be a pivotal initial event in the development of DAP resistance. With the hypothesis that clinical enterococcal isolates with DAP MICs between 3 and 4 μg/ml might harbor mutations in liaFSR, we studied 38 Enterococcus faecium bloodstream isolates, of which 8 had DAP MICs between 3 and 4 μg/ml by Etest in Mueller-Hinton agar. Interestingly, 6 of these 8 isolates had predicted amino acid changes in the LiaFSR system. Moreover, we previously showed that among 6 DAP-resistant E. faecium isolates (MICs of >4 μg/ml), 5 had mutations in liaFSR. In contrast, none of 16 E. faecium isolates with a DAP MIC of ≤2 μg/ml harbored mutations in this system (P < 0.0001). All but one isolate with liaFSR changes exhibited DAP MICs of ≥16 μg/ml by Etest using brain heart infusion agar (BHIA), a medium that better supports enterococcal growth. Our findings provide a strong association between DAP MICs within the upper susceptibility range and mutations in the liaFSR system. Concomitant susceptibility testing on BHIA may be useful for identifying these E. faecium first-step mutants. Our results also suggest that the current DAP breakpoint for E. faecium may need to be reevaluated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664970      PMCID: PMC3421602          DOI: 10.1128/AAC.00509-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.

Authors:  James S Lewis; Aaron Owens; Jose Cadena; Kathryn Sabol; Jan E Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites.

Authors:  B E Murray; K V Singh; J D Heath; B R Sharma; G M Weinstock
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

3.  Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR.

Authors:  S Dutka-Malen; S Evers; P Courvalin
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function.

Authors:  B E Murray; K V Singh; R P Ross; J D Heath; G M Dunny; G M Weinstock
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

6.  Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin.

Authors:  P C Kohner; R Patel; J R Uhl; K M Garin; M K Hopkins; L T Wegener; F R Cockerill
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

7.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

Authors:  James H Jorgensen; Sharon A Crawford; Cynthia C Kelly; Jan E Patterson
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Genomic and SNP analyses demonstrate a distant separation of the hospital and community-associated clades of Enterococcus faecium.

Authors:  Jessica Galloway-Peña; Jung Hyeob Roh; Mauricio Latorre; Xiang Qin; Barbara E Murray
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

View more
  57 in total

Review 1.  Treatment of Vancomycin-Resistant Enterococci: Focus on Daptomycin.

Authors:  Rose M Kohinke; Amy L Pakyz
Journal:  Curr Infect Dis Rep       Date:  2017-10       Impact factor: 3.725

2.  A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis.

Authors:  Jinnethe Reyes; Diana Panesso; Truc T Tran; Nagendra N Mishra; Melissa R Cruz; Jose M Munita; Kavindra V Singh; Michael R Yeaman; Barbara E Murray; Yousif Shamoo; Danielle Garsin; Arnold S Bayer; Cesar A Arias
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

Review 3.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

Review 4.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

5.  Disrupting Membrane Adaptation Restores In Vivo Efficacy of Antibiotics Against Multidrug-Resistant Enterococci and Potentiates Killing by Human Neutrophils.

Authors:  Sandra Rincon; Diana Panesso; William R Miller; Kavindra V Singh; Melissa R Cruz; Ayesha Khan; An Q Dinh; Lorena Diaz; Rafael Rios; Yousif Shamoo; Jinnethe Reyes; Truc T Tran; Danielle A Garsin; Cesar A Arias
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

Review 6.  Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.

Authors:  Jose M Munita; Barbara E Murray; Cesar A Arias
Journal:  Int J Antimicrob Agents       Date:  2014-09-02       Impact factor: 5.283

Review 7.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

8.  Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Razieh Kebriaei; Jordan R Smith; Katherine Lev; T T Tran; Warren E Rose; Cesar A Arias; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

Review 10.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.